Unknown

Dataset Information

0

Inverse correlation between trabecular bone volume and bone marrow adipose tissue in rats treated with osteoanabolic agents.


ABSTRACT: There is currently an unmet clinical need for improved treatments for skeletal diseases such as osteoporosis and cancer-induced bone disease. This is due in part to a paucity of novel targets and an incomplete understanding of the mechanisms of action for established therapies. We defined the effects of anabolic treatments on bone and the bone marrow adipocyte (BMA). Sclerostin-neutralizing antibodies (Scl-Ab), romosozumab, human parathyroid hormone (hPTH, 1-34), and hPTH/hPTHrP analogues (e.g. teriparatide and abaloparatide) stimulate bone formation and have been studied in clinical trials for severe osteoporosis. In this study, eight-week-old male and female rats were administered vehicle, Scl-Ab (3?mg/kg or 50?mg/kg) weekly, or hPTH (1-34) (75??g/kg) daily for 4 or 26?weeks. Histological analyses of distal femura were performed using a novel ImageJ method for trabecular bone and bone marrow adipose tissue (BMAT). Adipocyte number, circumference, and total adipose area were compared within the tissue area (T.Ar) or the marrow area (Ma.Ar), (defined as the T.Ar minus the trabecular bone area). After 26?weeks of treatment, a significant inverse correlation between bone and tissue adiposity (total adipocyte area divided by T.Ar) were observed in males and females (p?

SUBMITTER: Costa S 

PROVIDER: S-EPMC6559822 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inverse correlation between trabecular bone volume and bone marrow adipose tissue in rats treated with osteoanabolic agents.

Costa Samantha S   Fairfield Heather H   Reagan Michaela R MR  

Bone 20190404


There is currently an unmet clinical need for improved treatments for skeletal diseases such as osteoporosis and cancer-induced bone disease. This is due in part to a paucity of novel targets and an incomplete understanding of the mechanisms of action for established therapies. We defined the effects of anabolic treatments on bone and the bone marrow adipocyte (BMA). Sclerostin-neutralizing antibodies (Scl-Ab), romosozumab, human parathyroid hormone (hPTH, 1-34), and hPTH/hPTHrP analogues (e.g.  ...[more]

Similar Datasets

| S-EPMC9640193 | biostudies-literature
| S-EPMC2613834 | biostudies-literature
| S-EPMC5783409 | biostudies-literature
| S-EPMC10393898 | biostudies-literature
| S-EPMC2835226 | biostudies-literature
| S-EPMC5847472 | biostudies-other
| S-EPMC3281873 | biostudies-literature
| S-EPMC5547068 | biostudies-literature
| S-EPMC6062483 | biostudies-literature
| S-EPMC10376979 | biostudies-literature